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Abstract
Diagnostic and prognostic biomarkers for cancer based on gene expression profiles are viewed as a major step towards a
better personalized medicine. Many studies using various computational approaches have been published in this direction
during the last decade. However, when comparing different gene signatures for related clinical questions often only a small
overlap is observed. This can have various reasons, such as technical differences of platforms, differences in biological
samples or their treatment in lab, or statistical reasons because of the high dimensionality of the data combined with small
sample size, leading to unstable selection of genes. In conclusion retrieved gene signatures are often hard to interpret from
a biological point of view. We here demonstrate that it is possible to construct a consensus signature from a set of
seemingly different gene signatures by mapping them on a protein interaction network. Common upstream proteins of
close gene products, which we identified via our developed algorithm, show a very clear and significant functional
interpretation in terms of overrepresented KEGG pathways, disease associated genes and known drug targets. Moreover, we
show that such a consensus signature can serve as prior knowledge for predictive biomarker discovery in breast cancer.
Evaluation on different datasets shows that signatures derived from the consensus signature reveal a much higher stability
than signatures learned from all probesets on a microarray, while at the same time being at least as predictive. Furthermore,
they are clearly interpretable in terms of enriched pathways, disease associated genes and known drug targets. In summary
we thus believe that network based consensus signatures are not only a way to relate seemingly different gene signatures
to each other in a functional manner, but also to establish prior knowledge for highly stable and interpretable predictive
biomarkers.
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Introduction
Diagnostic and prognostic biomarkers for cancer based on
patient gene expression profiles are viewed as a major step towards
a better personalized medicine. Identification of disease-subtypes
and risk stratification of patients based on specific biomarker gene
signatures has the potential to help medical doctors to find an
individually optimized treatment, to avoid unnessery medication
and to reduce costs [1–3].
A wealthofgene expression data forpatients isnowadayspublicly
available through databases such as Gene Expression Omnibus
[4,5], ArrayExpress [6] and The Cancer Genome Atlas (TCGA).
Recently, GeneSigDB [7] has been established as a database
systematically integrating gene signatures (i.e. lists of genes being
together associated with a certain phenotype) from various
publications leading to a rich resource for meta analysis and high
level comparisons. Several authors have mentioned the small
overlap when comparing gene signatures from different studies [8–
10]. This imposes a difficulty for interpretation and validation of
gene signatures, since in general biomarker research has two major
goals: first, identification of stable and robust disease markers (i.e.
molecules, which are causally linked to the disease phenotype), and
second, discovery of targets for potential therapies. For both
purposes biomarkers are required to be reproducible [11].
Major differences between gene signatures for related disease
phenotypes can in principal have various reasons [12]: (1)
Different chip platforms could have been used, which may imply
non-identical sets of measured transcripts and thus can lead to
systematic differences in obtained gene signatures. (2) The
biological material may show certain systematic differences
between microarray studies. If, for example, breast cancer patients
in one study have a higher average age than in another study, this
may lead to differences in gene expression. (3) Experimental
protocols may differ between laboratories. (4) Microarray data is
very high dimensional and thus establishing a statistically stable
gene signature is a severe problem in the light of usual small
sample sizes. Depending on the chosen technique, minimal
changes of dataset 1 versus dataset 2 may thus lead to drastic
changes of obtained gene signatures.
Despite of this fact it was found that on a functional level (e.g.
dis-regulated pathways) gene signatures with small overlap can be
rather similar [9,13]. This motivated us to investigate two
questions: (1) Is it possible to derive a consensus signature from a
set of published prognostic gene signatures and does this consensus
signature exhibit functional enrichment of disease related genes
and known drug targets? (2) Can this consensus signature be used
as prior knowledge to derive predictive gene signatures, which
have a high stability and are easy to interprete?
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25364Table 1. Overview about used gene signatures.
Signature PMID predicts #Patients #Entrez IDs
Bertucci et al. 12538167 long vs. short term survival 34 21
Li et al. 18278552 recurrence 93 28
Huang et al. 12747878 recurrence 89 148
Van’t Veer et al. 11823860 long vs. short term survival 117 60
Wang et al. 15721472 metastasis occurrence 115 75
Sotiriou et al. 16478745 histologic grade 189 223
The last column shows the number of unique Entrez Gene IDs.
doi:10.1371/journal.pone.0025364.t001
Figure 1. Enrichment of ‘‘cancer’’, ‘‘breast cancer’’ and ‘‘primary tumor’’ related genes in consensus and original signatures
(hypergeometric test). Only Disease Ontology terms are depicted, which map to at least 2 genes from a signature. The black line indicates a 5%
significancethreshold (after Bonferroni correction). Thefull list ofallenrichedDiseaseOntologyterms withBonferroni correctedp,5%isavailableinTableS1.
doi:10.1371/journal.pone.0025364.g001
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which clusters genes from different gene signatures based on their
shortest path distances in a protein-protein interaction network. For
each cluster we then identify so-called lowest-common ancestors
(LCAs), which are proteins that are commonly upstream of a set of
proteins and thus may exhibit a certain regulatory influence (provided
they are not too far away). This idea has a certain similarity with the
master regulator analysis (MRA) algorithm proposed in a different
context for reconstruction of disease specific TF-target networks [14].
The set of LCAs, eventually joined with the set of genes appearing in
the majority of signatures, forms our consensus signature. Our
hypothesis, which we verified here by looking at six signatures related
to breast cancer prognosis [15–20], was that genes in such a consensus
are enriched for genes that are known to be disease associated.
Moreover, we found a strong enrichment of known drug targets.
Having verified this first hypothesis we went on to test our second
hypothesis, namely that genes in the consensus signature can be
used to guide development of predictive gene signatures in breast
cancer, which are interpretable and stable. This hypothesis was
verified in three independent gene expression datasets [21–23].
These derived signatures not only showed a significant overlap, but
were also more stable with respect to selected genes than signatures
learned from the full set of probesets on a microarray. Furthermore,
signatures derived from the consensus signature showed a high
fraction of disease related genes and targets for therapeutic
compounds, which highlights the possibility to interpret them easily.
Results
Network Based Consensus Signature is Disease Related
and Enriched for Known Drug Targets
Six gene signatures related to breast cancer prognosis, namely
[15–20], were retrieved in standardized format (ENSEMBL
identifiers) from GeneSigDB. An overview about these signatures
Figure 2. Enrichment of cancer related pathways in consensus and original signatures (hypergeometric test). Only signficantly
enriched pathways are depicted. The black line indicates a 5% FDR significance threshold (Benjamini-Yekutieli method). The full list of all enriched
KEGG pathways with FDR,5% is available in Table S3.
doi:10.1371/journal.pone.0025364.g002
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and mapped them to a large protein interaction network compiled
from a merger of the Pathway Commons database [24] with non-
metabolic KEGG pathways (see Section Methods). These six
signatures together contained 504 genes, among which 28
appeared more than once and 17 three times. There was no
overall overlap between signatures, and no gene appearing in
more than half of the signatures.
An algorithm was developed for deriving a network based
consensus signature from these six signatures consisting of lowest
common anchestors (LCAs). Details of the algorithm as well as a
computational study investigating features of its principal perfor-
mance are described in the Methods Section of this paper.
Application of this algorithm yielded a consensus signature with
203 genes (Table S1), which was investigated further.
We used the tool FunDO [25] to look for enrichment of disease
related genes (Table S2). FunDO uses a hypergeometric test. This
revealed a high enrichment of cancer (36 genes, Bonferroni corrected
p,1e-22) and specifically breast cancer related genes (21 genes,
Bonferroni corrected p,1e-12). Interestingly enough the enrichment
of cancer and breast cancer genes was even higher in the consensus
signature than in the original signatures (Figure 1). A further analysis
of enriched KEGG pathways (hypergeometric test, Figure 2) also
showed a high enrichment of ‘‘Cell cycle’’ (FDR,1e-13, multiple
testing correction by Benjamini-Yekutielimethod [26]),‘‘Pathways in
cancer’’ (FDR,0.001), ‘‘TGF-b signaling pathway’’ (FDR,0.01),
‘‘Focal adhesion’’ (FDR,0.01), ‘‘Oocyte meiosis’’ (FDR,0.001) and
‘‘p53 signaling pathway’’ (FDR,0.05),which have all been related to
breast cancer [27–30]. Interestingly, the only other signature showing
sucha strong enrichment of cancer related KEGGpathways was that
of Sotiriou et al., whereas the signature by Bertucci et al. showed a
much weaker enrichment (‘‘ErbB signaling’’, ‘‘Pathways in cancer’’,
‘‘Adheres junction’’ with FDR,0.05) and the others revealed no
enrichment at FDR cutoff 5%. In other words, no commonly
enrichedpathways could befound amongthesixpublished signatures
investigated here.
Figure 3. Enrichment of drug targets in consensus and original signatures (hypergeometric test). The black line indicates a 5%
significance threshold. The full list of all drug targets and therapeutic compounds is available in Table S4.
doi:10.1371/journal.pone.0025364.g003
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compounds against breast cancer in our consensus signature. For
that purpose we retrieved a list of 104 proteins and respective
therapeutic compounds in breast cancer, which are either in
clinical trials (also withdrawn ones), FDA approved or on the
market with the help of the software MetaCore (see Supplement
S1 and Table S4). Application of Fisher’s exact test revealed a high
over-representation of such drug targets within our consensus
signature (p,1e-10). This was interestingly higher than for all
other signatures (Figure 3). Signatures by Wang et al. and Huang
et al. did not show any enrichment of known drug targets.
Network Based Consensus Signature Can Guide
Predictive Biomarker Development
Microarray Data. We next sought out to investigate, in how
far a network based consensus signature can be used to guide
developmentofprognosticgenesignatures.Forthatpurposewetook
three independent microarray datasets, which had not been used to
establish any of our above investigated signatures. These were the
data by Ivshina et al. [21] (249 patients), Schmidt et al. [22] (‘‘Mainz
dataset’’;200 patients) and Pawitan etal.[23](159 patients).Alldata
were measured on the Affymetrix HGU133A chip platform,
downloaded from GEO and normalized via FARMs [31].
Predictive Power and Stability. We used SAM [32] to
identify probesets being differentially expressed between different
clinical groups of patients with a q-value cutoff of 5%. Depending on
the available information at GEO for each dataset these groups were
defined slightly different: On the Mainz dataset we tried to
discriminate patients with distant metastasis-free survival ,5y e a r s
(46 patients) from patients with longer distant metastasis-free survival
(154 patients). On the Ivshina and Pawitan datasets we looked for
differentially expressed probesets between patients suffering from a
disease recurrence within 5 years (Ivshina: 90, Pawitan: 40) from
those, with longer relapse-free survival (Ivshina: 159, Pawitan: 119).
Only probesets corresponding to genes in our consensus signature
were used. Given these probesets we then trained a Support Vector
Figure 4. Prediction performance of differentially expressed probesets within our consensus signature (Consensus). All refers to a
signature derived from all probesets on the microarray. All signatures were trained and tested within a cross-validation procedure.
doi:10.1371/journal.pone.0025364.g004
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the range 10
24,10
23,…10
2 via 5-fold cross-validation.
We evaluated the prediction performance of this approach
within a cross-validation scheme on each of the above described
datasets: Each dataset was randomly split into 10 folds and each
fold successively left out once for testing, while the others were
used for training (SAM analysis plus subsequent SVM training).
The whole procedure was repeated 10 times (10 times repeated
10-fold cross-validation). Predictions were then evaluated in terms
of area under ROC curve (AUC). This showed a performance of
our approach being significantly better (Mainz and Pawitan
datasets, p,0.05-Wilcoxon signed rank test) or at least comparable
(Ivshina dataset) as if differentially expressed probesets among all
probesets on the microarray were identified and used for SVM
training (Figure 4). That means our consensus signature was not
only interpretable, but also contained a predictive signal.
An analysis of the frequency, by which individual probesets were
selected within the cross-validation procedure clearly revealed a
higher stability compared to a signature constructed from all
probesets on the microarray (Figure 5): On the Ivshina dataset the
fraction of constantly chosen probesets was 50% among all those that
were ever selected. On the Pawitan and Mainz dataset the fraction
was around 40%. In contrast, learning a signature from all probesets
on the microarray yielded only a fraction of
,10% constantly chosen
probesets on the Ivshina and below 5% on the other datasets. This
result is not unexpected: Most genes are unable to perfectly separate
patient groups individually. Then, depending on the selected set of
patients, they may sometimes appear as significant, sometimes not,
which makes gene selection unstable. Therefore, it is natural that
restricting the set of probesets by some sort of prior knowledge (as we
did here) increases gene selection stability.Our approach may thus be
understood as a specific kind of regularization [33], in which model
complexity (here: maximal number of genes in a gene signature,
which is upper bounded by the size of the consensus signature) is
restricted in order to increase the possibility to identify a good fitting
classifier with high stability. The whole idea can be illustrated further
by a simulation, in which we compared stabilities of randomly
selected signatures from the whole microarray against randomly
Figure 5. Stability of probeset selection: The x-axis shows the number of times a probeset is selected within a 10610-fold cross-validation
procedure (i.e. 100 times at maximum). The y-axis depicts the fraction of probesets, which have been selected as often as indicated on the x-axis.
doi:10.1371/journal.pone.0025364.g005
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detailed description in Supplement S1 and Figure S1).
Functional Analysis. We further had a closer look at the
individual signatures derived from the consensus signature (Tables S5,
S6, S7). For that purpose we ran a SAM analysis on each of the three
microarray datasets without cross-validation, only using probesets of
our consensus signature. This yielded 111 genes (175 probesets) for the
Ivshina data set, of which FunDO could relate 26 to cancer
(Bonferroni corrected p,1e-19, see Table S7) and 10 to breast
cancer (Bonferroni corrected p,1e-4). Moreover, the signature
contained 7 known targets for therapeutic compounds (enrichment:
p,2.2e-16), namely HSP90AA1(e.g. Retaspimycin, Tanespimycin,
Alvespimycin – see Table S5), TOP2A (e.g. Esorubicin, Ciprofloxacin),
ERBB2 (e.g. Trastuzumab, Pertuzumab, Gefitinib), TUB4A1A (e.g.
Estramustine), TUBA1B (e.g. Eribulin, Paclitaxel), CDK2 (e.g.
Indisulam) and EGFR (e.g. Erlotinib, Gefitinib). KEGG analysis
revealed a high enrichment of ‘‘Cell cycle’’ (FDR,1e-10),
‘‘Progesterone-mediated oocyte maturation’’ (FDR,0.001), ‘‘Oocyte
meiosis’’ (FDR,0.01) and ‘‘Pathways in cancer’’ (FDR,0.01).
For the Mainz dataset we obtained 69 genes (101 probesets), of
which FunDO could relate 18 to cancer (Bonferroni corrected
p,1e-14) and 3 specifically to breast cancer. Moreover, the
signature contained 3 known targets for therapeutic compounds
(enrichment:p,1e-4),namelyTOP2A,CDK2andTUBA1B.KEGG
analysis revealed an enrichment of ‘‘Cell cycle’’ (FDR,1e-10),
‘‘Progesterone-mediatedoocytematuration’’(FDR,0.01),‘‘Oocyte
meiosis’’ (FDR,0.01) and ‘‘p53 signaling pathway’’ (FDR,0.05).
Analysis of the Pawitan dataset yielded 78 genes (113 probesets),
of which FunDO could relate 19 to cancer (Bonferroni corrected
p,1e-14), 2 to primary tumors (Bonferroni corrected p,0.05) and
8 specifically to breast cancer (Bonferroni corrected p,1e-4). The
signature contained 4 known targets for therapeutic compounds
(enrichment: p,1e-14), namely HSP90AA1, TOP2A, TUBA1B and
CDK2 (Table S7). Enriched KEGG pathways were again ‘‘Cell
cycle’’ (FDR,1e-9), ‘‘Progesterone-mediated oocyte maturation’’
(FDR,0.001) and ‘‘Oocyte meiosis’’ (FDR,0.001).
Altogether these results revealed that predictive biomarker
signatures derived from the consensus signature, showed a clear
diseaseassociationintermsofenriched pathways,therapeutictargets
and disease related genes. Moreover, there was a high consistency in
enriched pathways, namely ‘‘Cell Cycle’’, ‘‘Progesterone-mediated
oocytematuration’’and ‘‘Oocytemeiosis’’.Even atthe gene level we
observed a significant overlap (Figure 6; p,1e-5). Significance was
determined here via a permutation test (see Methods).
The results presented in this paragraph generally met our
expectations, since all signatures were derived from the consensus
signature, which has already been shown to be highly enriched for cancer
related pathways, disease related genes and therapeutic drug targets.
Discussion
In this work we demonstrated that it is possible to derive a
consensus signature from seemingly different prognostic gene
signatures in breast cancer by taking into account knowledge on
protein-protein interactions. Our approach is based on the idea,
that genes from different signatures can be clustered in the context
of a protein interaction network and that meaningful representa-
tives for these clusters can be found by looking for close, common
upstream genes. Application of this method to six published gene
signatures and subsequent enrichment analysis revealed a clear
association of our consensus signature to breast cancer related
genes, pathways and targets for therapeutic compounds.
We demonstrated that network based consensus signatures can
be useful as prior knowledge for prognostic biomarker discovery.
We suppose that the same framework could likewise be used in the
context of diagnostic biomarker discovery (disease subtype identi-
fication). On our investigated datasets the cross-validated prediction
performance with our approach, where only differentially expressed
probesets within the consensus signature were considered, was at
least comparable as if differentially expressed probesets from the
whole microarray were taken into account. Moreover and most
importantly, gene selection stability was significantly higher. The
retrieved final signatures were meaningful in terms of enriched
pathways, drug targets and breast cancer related genes.
In summary we thus believe that looking for consensus
signatures among published gene signatures from the literature is
not only a possibility to establish a functional relationship between
these signatures, but also offers a valuable source of prior
knowledge for biomarker discovery in breast cancer and thus
can bring us a bit closer to the ultimate goal to obtain an
interpretable, stable and highly predictive gene signature for
patient stratification according risk groups and disease subtypes. It
remains, however, an open question for future work, in how far
our presented results can be generalized to other disease entities.
Materials and Methods
Protein Interaction Network
Within this work we employ protein interaction data as our basic
knowledge resource. In our case a protein interaction network was
compiled from a merger of all non-metabolic KEGG pathways [34]
– only gene-gene interactions were considered – together with the
Pathway Commons database [24], which was downloaded in tab-
delimited format (May2010). The purposewas toobtain an as much
as possible comprehensive network of known protein interactions.
For the Pathway Commons database the SIF interactions INTER-
ACTS–WITH and STATE–CHANGE were taken into account
Figure 6. Overlap of signatures derived from the consensus
signature. The total overlap between all three signatures was
significant with p,1e-5.
doi:10.1371/journal.pone.0025364.g006
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and any self loops removed. For retrieval and merger of KEGG
pathways we employed the R-package KEGGgraph [35].
In the resulting network graph (13,840 nodes with 397,454 edges)
we have directed as well as undirected edges. For example, a
directed edge ARB could indicate that protein A modifies protein B
(e.g. via phosphorylation). An undirected edge A2B implies a not
further specified type of direct interaction between A and B. Nodes
in this network are identified via Entrez gene IDs. Genes in gene
signatures can be thus be mapped to our protein interaction graph.
Genes, which cannot be mapped, are not considered further.
We also investigated to expand this network further by putative
transcriptionfactor(TF)-target gene interactions, butoursimulation
study (see below) in this case clearly revealed an inferior
performance compared to using a protein-protein interaction
network only. This is probably due to the high number of false
positives among inferred TF-target associations. Details can be
found in the Supplement S1 to this paper (Figure S2).
Algorithm 1 Pseudocode for anetworkbased consensussignature.
ConsensusSignatures(S,G,k)
Input:
S = set of gene signatures
G = partially directed graph (protein interaction network)
k = path distance cutoff (here 2)
consensus r genes appearing in .50% of all signatures
candidates r S{{consensus}
D r shortest path distance matrix between candidates (ignoring
edge directions)
H r complete linkage clustering tree of candidates w.r.t. D
for h r1…maximal pathway distance:
cut H at height h and obtain clusters
C/ clusters contaning genes from more than one signature
for each c[C:
consensus r consensus | LCA(c,k) # note that the LCA can
be empty
return consensus
Figure 7. Enrichment of disease associated genes and drug targets in dependency on the number of gene signatures considered
for a consensus.
doi:10.1371/journal.pone.0025364.g007
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Algorithm. Let S be a set of gene signatures and G be a
partially directed graph (protein interaction network). A k-common
ancestor(k-CA) ofa setofnodesN(S isdefinedasthat setofnodes
inG,fromwhichall nodesinN canbe reachedwithinpath distance
k. Each c[k-CA has thus a particular shortest path distance to each
n[N, which is at most k (here k=2). We define the LCA of N
(abbreviated as LCA(N,k)) as a subset of the k-CA. More
specifically, each g[LCA(k-CA has to fulfill the additional
criterion that the average shortest path distance to all nodes in N
is minimal. Having this defined our algorithm works as described in
pseudo code 1. The main idea is to successively look for groups of
genes stemming from different signatures, which are close with
respect to their shortest path distances in the network. Foreachsuch
group we look for the LCA. Please note that the LCA does not need
to be a non-empty set, because we have a defined path distance
cutoff k. The likelihood of the LCA being empty obviously increases
with higher spread of genes over the network.
Groups of genes are identified here by cutting a complete
linkage clustering tree at a particular height. The choice of
complete linkage clustering guarantees that we tend to get
compact groups of approximately equal diameters (i.e. maximal
shortest path distances between any pair of genes) [36]. This
makes it more likely to find an LCA, which may show a certain
regulatory influence on downstream genes.
The overall aim of our algorithm is to identify a consensus
signature, which is enriched for genes being associated with the
disease. Our hypothesis here is that LCAs together with genes
appearing in the majority of gene signatures (‘‘majority signature’’)
are good candidates for such a purpose.
The R-implementation of the proposed algorithm is part of the
Supplements to this paper (code S1).
Performance Study. We investigated the principal perfor-
mance of our algorithm in terms of enrichment of disease associated
genes and known drug targets in dependency on the number of gene
signatures considered for the consensus. For this purpose from the six
above described gene signatures we randomly picked 2,3,…,6 ones
without replacement. For the picked gene signatures we then ran our
algorithm and looked for significant enrichment of disease associated
genes and drug targets. The procedure was repeated 100 times. This
revealed a clear increase of significance in dependency on the number
of gene signatures considered for a consensus (Figure 7), which implies
that our algorithm picked up more and more disease relevant
information. We would like to point out that not onlythe enrichment of
cancer, but specifically also of breast cancer related genes increased
with the number of used gene signatures. This means that not only the
sensitivity, but also the specificity of the consensus signature was
i m p r o v e dt h em o r eg e n es i g n a t u r e sw e r ec o n s i d e r e d .
The existence of the majority signature, i.e. the signature
containingonly genesappearing in.50%ofallcomparedsignatures,
varied greatly and with no clear trend depending on the number of
compared signatures (Figure 8). Interestingly enough, in cases, where
a majority signature could be established, it generally did not show
anyenrichmentofdiseaseassociatedgenesanddrugtargets(Figure9).
This suggests that even in cases, where it is possible to compute a
majority signature, our algorithm offers an additional benefit.
Significance of Overlap
The significance of an overlap between a set of n signatures was
determined via a random permutation test: We sampled 100,000
Figure 8. Fraction of times that a majority signature could be computed in dependency on the number of signatures.
doi:10.1371/journal.pone.0025364.g008
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EntrezgeneIDsavailableontheHGU133Achip.Eachtimethesize
ofthe overlapwasdetermined and intheend counted,howoftenthe
overlap of randomly sampled signatures exceeded the overlap of the
original signatures. This yielded an empirical p-value, which was
further corrected via the method by Phipson and Smyth [37].
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